Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis

Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know

Tue, October 27, 2026 at 1:00 PM UTC 4 min read

Madrigal Pharmaceuticals (MDGL) is expected to report negative earnings in the upcoming week, raising concerns among investors about the company's financial health. This anticipated downturn could impact investor sentiment, especially given the company's ongoing clinical trials and development efforts. Investors should closely monitor the earnings report for insights into Madrigal's progress and any potential implications for its future growth and stock performance.

Read full article →

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

Thu, September 10, 2026 at 4:20 PM UTC 4 min read

Madrigal Pharmaceuticals (MDGL) has seen a significant increase in interest from institutional investors, indicating growing confidence in the company's potential. This surge in investment could signal a positive outlook for MDGL's future performance, particularly as it advances its clinical programs. For investors, this trend may suggest a favorable opportunity to consider adding MDGL to their portfolios, given the backing from major financial institutions.

Read full article →